Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALZ-801 in Healthy Elderly Subjects
NCT04157712Phase 1Completed
- Sponsor
- Alzheon, Inc.
- Start
- Sep 2015
- Primary completion
- Jul 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of valiltramiprosate in Alzheimer's disease (AD) (4 cohorts), sponsored by Alzheon, Inc. Primary endpoints: Number of participants with adverse events at 7 days, Maximum Plasma Concentration (Cmax) at Day 14 and 4 more. Started Sep 2015; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04157712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157712.